Synthetic Biologics releases study results for SYN-004
SYN-004 was tested on 10 patients. The study showed the therapeutic decreased digestive fluid in the small intestine, which decreased negative effects, while not reducing the therapeutic levels of antibiotic in the bloodstream. SYN-004 in both lower and higher doses was tolerated well by the test subjects.
The antibiotics with which SYN-004 were tested are typically used to treat C. difficile infections (CDI) and diarrhea caused by antibiotic use.
"The completion of the first Phase 2a clinical trial for SYN-004 is an important achievement for Synthetic Biologics," Jeffrey Riley, president and CEO, said. "The second Phase 2a clinical trial for SYN-004 is currently ongoing to evaluate the GI antibiotic-degrading effects and the safety of SYN-004 in the presence of the proton pump inhibitor (PPI), esomeprazole, in participants with functioning ileostomies. We anticipate reporting topline results from the second Phase 2a of SYN-004 during the first half of 2016."
More information about Synthetic Biologics and SYN-004 is available online at www.syntheticbiologics.com.
Organizations in this story
Synthetics Biologics, Inc. 9605 Medical Center Dr Rockville, MD - 20850-2959